News

BioRestorative Therapies, Inc: Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on ...
ALS drug testing in patient-derived cells provides personalized window into nervous system
Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating ...
Organoids Market Surges with Applications in Disease Modeling and Personalized Medicine - Download Insights Today! Valuates Reports
Organoids Market is Segmented by Type (Stem Cell Source, Tumor Cell Source), by Application (Biopharmaceutical Companies, Academics and Research Institutes, Hospital).
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative ...
Baylor College of Medicine5h
Let-7 is a key guardian of healthy lungs that keeps pulmonary fibrosis in check
Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is involved in lung repair and in ...